At Gertrude Biomedical our strategy is focused on modulating key gene 'switches' also known as transcription factors. This approach has the potential to identify novel therapeutics to treat diseases of unmet medical need.
Gertrude Biomedical is dedicated to developing novel small molecule inhibitors of the SOX18 transcription factor complex, targeting genes that build blood & lymphatic vessels. This approach 'short circuits' the gene programs that promote pathological vessels in disease, providing the potential to treat human diseases that depend on aberrant vasculature for their growth and spread.
Company Details
- Employees
- 18
- Founded
- -
- Address
- Level 6 12-20 Flinders Lane, Melbourne,victoria 3000,australia
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- gertrudebiomed.com
- HQ
- Melbourne, Victoria
Gertrude Biomedical Questions
Gertrude Biomedical's website is gertrudebiomed.com
Gertrude Biomedical's LinkedIn profile is https://au.linkedin.com/company/gertrude-biomedical
Gertrude Biomedical has
18 employees.
View email and phone details for 18
employees at Gertrude Biomedical.
Gertrude Biomedical's industry is
Biotechnology Research
Gertrude Biomedical's top competitors are
Telix Pharmaceuticals Limited,
Inosi Therapeutics Pty Ltd,
Carina Biotech,
Cell Therapies Pty Ltd,
Kira Biotech Pty Ltd,
Amplia Therapeutics Limited,
Ternarx,
Oncology One Pty Ltd,
Rhythm Biosciences Limited,
Biocurate Pty Ltd.
Gertrude Biomedical's categories are Biotechnology Research
Gertrude Biomedical's founding year is 2019
